Aisling Capital
VC Fund
New York, United States
Aisling Capital is a VC fund in New York focused on Biotechnology and Health Care. Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leadingto rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
- Total investments:
- 117
- Last investment:
- Lead investor:
- 21%
- Fund size:
- $280M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Aisling Capital invests in
Stages Aisling Capital invests in
Countries Aisling Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Schiff
|
|||
Ayman Sabi
|
|||
Eric Aguiar
|
|||
Jan Hoerrner
|
|||
Scott Braunstein
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Biotechnology 65 (56%)
- Health Care 50 (43%)
- Pharmaceutical 34 (29%)
- Therapeutics 27 (23%)
- Medical 22 (19%)
Stage
- Series B 24 (21%)
- Series C 22 (19%)
- Post-IPO Equity 14 (12%)
- Series A 13 (11%)
- Funding Round 12 (10%)
Country
- United States 71 (61%)
- Switzerland 3 (3%)
- United Kingdom 2 (2%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew Schiff
Managing Partner
|
Managing Partner | Total investments: 12 | Find email | |
|
Ayman Sabi
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
|
Eric Aguiar
Partner
|
Partner | Total investments: 9 | Find email | |
|
Jan Hoerrner
Director of Investor Relations & Marketing
|
Director of Investor Relations & Marketing | Total investments: 0 | Find email | |
|
Scott Braunstein
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Claris Biotherapeutics
|
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M / Series B / Jul 28, 2026 | |
Wugen
|
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cellmalignancies. | $115M / Series C / Aug 27, 2025 | |
Scholar Rock
|
Scholar Rock, Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our newly elucidated understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietaryplatform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. We believe this approach, acting in the disease microenvironment, avoids the historical challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. We are advancing our lead product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy, or SMA. We expect to initiate a Phase 1 clinical trial in the second quarter of 2018. Utilizing our proprietary platform, we are also creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including other neuromuscular disorders, cancer, fibrosis and anemia. | $300M / Post-IPO Equity / Oct 08, 2024 | |
|
GondolaBio
|
GondolaBio researches, develops and manufactures pharmaceutical products. | $300M / Venture - Series Unknown / Aug 16, 2024 | |
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $55M / Post-IPO Equity / Jan 22, 2024 | |
Mindful Health Solutions
|
Mindful Health Solutions provides psychiatric treatments to people suffering from depression and other mental health issues. Their services include Transcranial Magnetic Stimulation (TMS therapy), SPRAVATO (esketamine) nasal spray, ketamine infusion therapy, and medication management. | Venture - Series Unknown / Jan 01, 2024 | |
Bicara Therapeutics
|
Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between thescientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation. | $165M / Series C / Dec 12, 2023 | |
Spyre Therapeutics
|
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies with the potential to revolutionize the treatment of inflammatory bowel disease (IBD). | $180M / Post-IPO Equity / Dec 07, 2023 | |
Stratus Therapeutics
|
Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases. | $62M / Series B / Feb 07, 2023 | |
Forge Biologics
|
Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups.It was founded in 2020 and headquartered inGrove City, Ohio. | $90M / Series C / Sep 12, 2022 | |
| See all 117 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Aisling Capital invest in?
Aisling Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 117 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Aisling Capital?
Public channels for Aisling Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Aisling Capital?
The team at Aisling Capital includes Andrew Schiff (Managing Partner), Ayman Sabi (Operating Partner) and Eric Aguiar (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
